Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PonchoPay aims to change the way parents pay for childcare and access the government funding they're entitled to.
Hundreds of millions of pounds of government support available to parents is going unspent each year due to poor awareness, clunky processes and a low adoption of technology. PonchoPay is making it easy for any source of funding to be aggregated at point of checkout, saving parents money and saving childcare providers a significant amount of time in the process.
Using Poncho Pay's intelligent automation engine, our vision is for parents to be able to quickly access and use this funding across all childcare providers that are registered to receive them nationwide.
As we build our prominent role in the payment journey, PonchoPay will be well positioned to offer additional services in future to parents and childcare providers alike. Growth capital and insurance solutions for childcare providers, Buy Now Pay Later for parents and AI-powered booking curation tools are a handful of additional revenue sources that we plan to explore in the future.
days to go:
Expired
investment:
£405,860
A wind turbine's generator currently uses rare-earth magnets which cost £40 per kg, Greenspur have developed innovative generators which use ferrite magnets, an abundantly available material, that cost as little as £1 per kg. The company have made further advancements by removing the gearbox, which has resulted in lower maintenance costs and improved efficiency.
days to go:
Expired
investment:
£368,640
A FCA-regulated digital bond marketplace offering investors high yield and senior secured bonds and loans in market-leading businesses. The WiseAlpha platform includes financial opportunities in companies such as Santander, Virgin Media, McLaren and EDF, amongst many other large brands. There are more than 4,000 members signed up to WiseAlpha, which offers interest returns between 3% and 15%.
At the British Banking Awards 2018, WiseAlpha was the winner of the Best Investments Provider Award and the company has been featured in many publications, including Bloomberg, The Financial Times, Moneyweek and City AM. WiseAlpha members can invest via depositing money from their bank account, or using their SIPP account. The company have also recently beta-launched 'Robowise', an automatic investment tool that will diversify a member's portfolio for them.
Funds are being raised for WiseAlpha to grow and expand the business. The company intends to enter into the European investment market, further develop their 'Robowise' tool and offer more products such as ISAs.
days to go:
Expired
investment:
£2,813,650
A financial assistant that helps you to save and invest money all from within an app. Plum connects to your existing bank account and uses machine learning to save money you're not spending every month by looking at your transactions history, without any input required.
days to go:
Expired
investment:
£1,005,249
OvuSense is a women's health monitoring platform offering continuous insights into the reproductive cycle. With over 45,000 users and 10 patents, they aim to expand through partnerships, starting with a large IVF clinic chain. Addressing underdiagnosed health issues, their platform provides accurate cycle monitoring, health screening, and treatment tracking. Backed by institutional investors, OvuSense stands out for its predictive capabilities and accuracy in ovulation tracking, empowering women's fertility control.
days to go:
Expired
investment:
£169,920
Nova launches growth focus, tech-enabled startups, putting passionate founders at the heart of everything they do. It creates a more rewarding experience for startups with its co-founding model. The company conceives and scales digital businesses thereby solving the real-world problems, open new markets and disrupt existing ones. 46% of Nova co-founded businesses are still trading. There are 140+ staff over Manchester, Liverpool, London, and Islamabad. There is a 3% portfolio valuation growth YOY, thereby creating more than £72m valuation of the portfolio. The company made a turnover of £7.2m in 2018/19. Nova is raising funds to leverage the company's growing network of Founders, Funds, and Talent in the UK.
days to go:
Expired
investment:
£744,880
